信迪利单抗和阿帕替尼治疗复发晚期食管癌患者的效果对比
Comparison of the Efficacy of Sintilimab and Apatinib in the Treatment of Patients with Recurrent Advanced Esophageal Cancer
张恒 1丁庆学 2陈春建 1李晓慧1
作者信息
- 1. 通许第一医院肿瘤科,河南 通许 475400
- 2. 鹤壁市中医院内科,河南 鹤壁 458030
- 折叠
摘要
目的:探讨信迪利单抗治疗复发晚期食管癌患者的效果及其对肿瘤标志物、神经元特异性烯醇化酶(NSE)及血管内皮细胞生长因子(VEGF)水平的影响.方法:选取于 2020 年 7 月—2022 年 7 月入通许第一医院接受信迪利单抗治疗的 43 例复发晚期食管癌患者作为试验组,同时回顾性选取于 2018 年 9 月—2019 年 12 月入我院接受阿帕替尼治疗的43例复发晚期食管癌患者作为对照组.比较两组临床疗效、肿瘤标志物水平、肿瘤细胞因子浓度以及毒副反应.结果:试验组DCR、ORR高于对照组,差异有统计学意义(P<0.05);治疗后,试验组CYFRA21-1、SCC、NSE、VEGF水平低于对照组,差异有统计学意义(P<0.05);试验组各毒副反应发生率与对照组比较,差异无统计学意义(P>0.05).结论:信迪利单抗治疗有助于降低复发晚期食管癌患者肿瘤标志物水平和肿瘤细胞因子浓度,增强临床疗效,并且具有一定的安全性.
Abstract
Objective:To investigate the effect of Sintilimab in the treatment of patients with recurrent advanced esophageal cancer and its effect on the levels of tumor markers,neuron-specific enolase(NSE)and vascular endothelial growth factor(VEGF).Methods:From July 2020 to July 2022,43 patients with recurrent advanced esophageal cancer who were admitted to Tongxu First Hospital for treatment with Sindili monoclonal antibody were selected as the experimental group.At the same time,43 patients with recurrent advanced esophageal cancer who were admitted to our hospital for treatment with apatinib from September 2018 to December 2019 were retrospectively selected as the control group.The clinical efficacy,tumor marker level,tumor cytokine concentration and toxic and side effects were compared between the two groups.Results:The DCR and ORR of the experimental group were higher than those of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CYFRA21-1,SCC,NSE and VEGF in the experimental group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of toxic and side effects between the experimental group and the control group(P>0.05).Conclusion:The treatment of Sindilimab is helpful to reduce the levels of tumor markers and tumor cytokine concentrations in patients with recurrent advanced esophageal cancer,enhance the clinical efficacy,and has certain safety.
关键词
食管癌/信迪利单抗/阿帕替尼/肿瘤标志物/肿瘤细胞因子浓度Key words
Esophageal cancer/Sindilimab/Apatinini/Tumor markers/Tumor cytokine concentration引用本文复制引用
出版年
2024
NETL
NSTL
万方数据